AGP Dialogue national : le président Oligui Nguema échange avec les membres du bureau AGP Gabon : Bientôt un recensement des biens de l’Etat AGP Coopération Gabon-France : un forum économique en perspective APS SENEGAL-PRESIDENTIELLE / Bassirou Diomaye Faye reçu en audience par Macky Sall MAP Afrique du Sud: Zuma exclu des prochaines élections (Commission électorale) MAP La CAF annonce les dates des finales de la Ligue des Champions et de la Coupe de la Confédération MAP Afrique du Sud: 45 morts dans un accident d’autocar au Limpopo APS SENEGAL-ITALIE-TRANSPORTS / ITA Airways va inaugurer en juillet une ligne Rome-Dakar APS SENEGAL-ENVIRONNEMENT / Bonne amélioration des taux d’accès à l’eau et à l’assainissement (expert) ANP Signature de convention entre le Niger et la Société WAPCO Niger pour un programme de formation de talents à Southwest Petroleum University de Chine

Mexico grants emergency approval for second coronavirus vaccine


  5 Janvier      32        Santé (15315),

 

Mexico City, Jan. 5, (dpa/GNA) – Mexico has granted emergency approval to the AstraZeneca/Oxford coronavirus vaccine, a Health Ministry official said, making it the second vaccine to get the go-ahead after the Pfizer/BioNTech jab.
On December 24, Mexico became the first country in Latin America to start vaccinations against Covid-19 – with doses from the vaccine produced by Germany-based BioNTech and US pharma giant Pfizer.
Almost 44,000 people have received the vaccine so far in Mexico, according to government figures.
Mexico has more than 1.4 million confirmed coronavirus cases and nearly 128,000 related deaths, according to Johns Hopkins University.
Britain, which was the first country to approve the AstraZeneca/Oxford jab, began vaccinating people with it on Monday.
In Latin America, Argentina and El Salvador have also already approved the vaccine. It is currently under review by European regulatory authorities.
The vaccine from the British-Swedish company AstraZeneca and the University of Oxford has shown slightly lower efficacy than the Pfizer/BioNTech preparation, but can be stored at higher temperatures and is cheaper. It is currently under review by European regulatory authorities.
GNA

Dans la même catégorie